International journal of clinical practice
-
Int. J. Clin. Pract. · Nov 2020
A Retrospective Analysis Comparing Persistence and Adherence to Treatment With Free- Versus Fixed-Dose Combination of an Alpha-Blocker and an Antimuscarinic Agent in Men With LUTS in Spain.
Combination therapy with an alpha blocker (AB) plus an antimuscarinic (AM) is recommended for men with moderate-to-severe mixed lower urinary tract symptoms (LUTS) when monotherapy is not effective in relieving storage symptoms. This study compared treatment persistence and adherence with an AB plus AM fixed-dose combination (FDC) vs an AB plus AM free-dose combination in men with LUTS in Spain. ⋯ Treatment with an AB/AM FDC is associated with better persistence and adherence vs a free-dose combination in men with LUTS in Spain.
-
Int. J. Clin. Pract. · Nov 2020
Criticality of physical/social distancing, handwashing, respiratory hygiene, and face-masking during the COVID-19 pandemic and beyond.
Physical/social distancing, handwashing, respiratory hygiene and face-masking have been recommended as realistic counterstrategies to control the COVID-19 pandemic. These strategies have been critical in the fight against the present pandemic in many countries. Here we detail the background to such countermeasures, present some examples in different settings and finally emphasise that they should remain in place worldwide as a cultural and behavioural "new normal" until a vaccine or a decisive treatment for COVID-19 is developed and made available globally.
-
Int. J. Clin. Pract. · Nov 2020
Use of Bisphosphonates and Other Bone Supportive Agents in the Management of Prostate Cancer - A UK Perspective.
To explore the practice and views of uro-oncologists in the UK regarding their use of bone supportive agents in patients with prostate cancer. ⋯ Uro-oncologists in the UK generally do not use bone supportive agents for men with metastatic hormone-naïve prostate cancer or those with non-metastatic disease. However, increasing the duration of ADT and the presence of castration-resistant metastatic prostate cancer increases use.